Navigation Links
New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C)

WASHINGTON, May 21, 2007 /PRNewswire/ -- A new study demonstrated that the active ingredient in Amitiza (lubiprostone), given 8 mcg twice a day, may improve symptom relief rates in adults with irritable bowel syndrome with constipation (IBS-C). These results were presented as a late-breaker at Digestive Disease Week 2007, the largest annual international meeting of digestive disease specialists.

"In this study, patients receiving lubiprostone were nearly twice as likely to achieve an overall response from symptoms of IBS-C compared to those receiving placebo," said Douglas A. Drossman, M.D., primary investigator, UNC Center for Functional GI and Motility Disorders, University of North Carolina, and the Chair of the Rome Committee. "As a result, lubiprostone may represent an important treatment for IBS-C sufferers."

IBS is a condition that affects approximately 58 million Americans and accounts for 25-50 percent of referrals to gastroenterologists. IBS-C symptoms include abdominal pain or discomfort associated with defecation or a change in bowel habits with features of disordered defecation.

Lubiprostone is a novel selective chloride channel activator that has been shown to be effective and well-tolerated in a number of well-controlled clinical trials in patients with chronic idiopathic constipation. Lubiprostone is marketed in the U.S. as AMITIZA, a 24-mcg gelcap that was approved for use for chronic idiopathic constipation in adults on January 31, 2006.

Sucampo Pharmaceuticals expects to submit a supplemental New Drug Application for IBS-C to the U.S. Food and Drug Administration by July 2007.

About the Study for IBS-C (lubiprostone 8 mcg)

In two phase III, multi-center, double-blind, randomized, placebo- controlled trials, 1,171 adults diagnosed with IBS-C (Rome II Criteria) were enrolled and received lubiprostone 8 mcg taken twice daily (783 adults) or placebo (388
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:5/6/2015)... South Africa , May 6, ... kills more people than HIV/AIDS, malaria and tuberculosis combined[1]. Approximately ... percent can be cured with the right treatment[3]. Together with ... are working to build up their radiation therapy infrastructures and ... cancer patients worldwide would benefit from radiation therapy[4] during the ...
(Date:5/6/2015)... May 06, 2015 Research and Markets ... of the "Asia-Pacific Internal Trauma Fixation Devices ... and Forecast To 2019" report to their ... Devices market is estimated to grow at a ... such as technological advancement, rising incidences of road ...
(Date:5/6/2015)... 6, 2015   GenSpera, Inc. (OTCQB: GNSZ) announced ... the national phase application process in 17 countries and regions, ... , China , Brazil ... When awarded, the resulting patent application will extend the exclusivity ... technology, including its lead drug candidate, mipsagargin, until 2033. ...
Breaking Medicine Technology:Elekta to bring cancer treatment to millions in Africa 2Elekta to bring cancer treatment to millions in Africa 3Elekta to bring cancer treatment to millions in Africa 4Asia-Pacific Internal Trauma Fixation Devices (Internal Trauma Fixation Plates, Screws, Rod Wires & Pins, Fusion Nails) Market 2015 2GenSpera Enters National Phase with Patent Application for Injectable Prodrug Formulations 2
... , June 21 Emdeon Inc. (NYSE: ... management solutions, today announced the acquisition of Chapin Revenue Cycle Management, ... leading technology-enabled provider of hospital-based revenue cycle services including accounts receivable ... , , ...
... Mich. , June 21 Action Fabricators ... the launch of Laminin Medical Products ( www.LamininMedical.com ), ... of medical products under contract with the Medical Device ... Development Corporation (MEDC) grant through their Economic Development Job ...
Cached Medicine Technology:Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 2Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 3Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 4Action Fabricators Expands its Footprint in the Healthcare Industry With the Launch of Laminin Medical Products 2
(Date:5/6/2015)... 06, 2015 vcfo, a specialized consulting ... and operational support to optimize business performance and productivity, ... Lynch and Michael Scheaffer. Both Lynch and Scheaffer have ... experience. , “We are delighted to add Jack ... CEO. “Leveraging their background in financial management and leadership, ...
(Date:5/6/2015)... 2015 Follow us on LinkedIn ... driven by the rising consumer awareness over the importance ... diseases. Hand washing is becoming a part of personal ... contracting infections. Periodic outbreak of Avian flu, Swine flu, ... virus disease (EVD) epidemic in West Africa are ...
(Date:5/6/2015)... California (PRWEB) May 06, 2015 In March, ... presenting at the 8th Milano Masterclass. As Europe’s most ... most elite plastic surgeons. Dr. Batniji was hand chosen ... Facial Plastic and Reconstructive Surgery, Dr. Pietro Palma. ... Milan, Italy. The conference hosts a diverse, multi-national faculty; ...
(Date:5/6/2015)... The 2015 STEMtech conference exhibition hall floor ... booth selection . Don’t miss this opportunity to highlight ... university decision-makers from around the country. , This year’s ... Arizona Grand in Phoenix. This beautiful all-suite hotel is ... of the South Mountain Preserve. The Phoenix area offers ...
(Date:5/6/2015)... Norcross, GA (PRWEB) May 06, 2015 ... has chosen Hexagon Geospatial technology to manage and distribute ... , Australia is one of the driest continents on ... supply through times of drought and erratic seasonal rainfalls ... water supply solutions. , Water NSW manages raw water ...
Breaking Medicine News(10 mins):Health News:vcfo Adds Two Senior Executives to Growing Team 2Health News:Growing Apprehension Amid Disease Outbreaks Drives Global Sales of Hand Sanitizers, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Apprehension Amid Disease Outbreaks Drives Global Sales of Hand Sanitizers, According to a New Report by Global Industry Analysts, Inc. 3Health News:Growing Apprehension Amid Disease Outbreaks Drives Global Sales of Hand Sanitizers, According to a New Report by Global Industry Analysts, Inc. 4Health News:California Surgeon Speaks at International Rhinoplasty Conference 2Health News:STEMtech Conference Exhibitors Gain Access to Community College and University Representatives From Across the U.S. 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 3
... WYE ) announced today that it will ... January 14, 2009 at 11:30 a.m. Eastern Time. ... and Pharmaceutical Business Units, Wyeth Pharmaceuticals. Wyeth,s presentation will ... and available for replay following the conference.Wyeth is one ...
... Jan. 8 (Nasdaq: WHRT ... has submitted an Investigational Device Exemption ("IDE") application to ... "Agency") for a pivotal Bridge-to-Transplant ("BTT") study of the ... includes detailed device information, including design and in ...
... We hear it everywhere: "What is your carbon footprint?" ... how can you reduce yours? It isn,t all that ... planning to bring it down.Listen to this report from Siemens ... can access video, audio, text, graphics and photos for free ...
... desk to prevent obesity: ovarian cancer. , ... ... has been set off by the medical community warning of America,s ... Cancer Institute completed a study that has shown a statistically significant ...
... been one of the most amazing recovery cases I have ... Otolaryngology, Dallas, TX , DALLAS, Jan. 8 In ... was laid off at Christmas and diagnosed with advanced stage ... I had cancer," says Hogland, tears welling up in his ...
... & Science University,s School of Dentistry ( www.ohsu.edu/sod ) ... and blood pressure synthesize a molecule known to be ... could someday play a significant role in the prevention ... pressure. According to the National Institutes of Health, SIDS ...
Cached Medicine News:Health News:Wyeth to Present at the JP Morgan Healthcare Conference 2Health News:WorldHeart Submits IDE Application for a Pivotal Bridge-to-Transplant Study of the Levacor(TM) VAD 2Health News:Treadmill Desks Combat Obesity Linked to Higher Rates of Ovarian Cancer 2Health News:Treadmill Desks Combat Obesity Linked to Higher Rates of Ovarian Cancer 3Health News:One Man's Determined Journey to Remission and a Renewed Sense of Faith 2Health News:OHSU School of Dentistry team discovers new molecule in blood-pressure control system 2
Elmed BC 50 M/M is an all purpose bipolar coagulator with a macro and micro mode. In the micro mode, the unit is ideally suitable for wet-field coagulation in ophthalmology, neurosurgery and other mi...
...
...
...
Medicine Products: